For example, the concomitant use of statins with fibrates9, 10, 11 or cytochrome P450 (CYP) inhibitors, such as clarithromycin (CYP3A4 inhibitor), cyclosporine (CYP3A4 inhibitor), and clopidogrel (CYP2C8 inhibitor), increases the risk of rhabdomyolysis.12, 13, 14 It has been reported that the increased risk of statin‐induced rhabdomyolysis may be due to the pharmacokinetic changes caused by concomitant drugs.15 If DDIs cause changes in the time‐course of blood concentration of statins, it not only changes the onset risk, but may also affect the onset timing. This evidence concerns the gene CYP3A4 and rhabdomyolysis.